Pearce IP BioBlast™: w/e 10 Apr 2020

by | Apr 13, 2020

Significant biosimilar activities this week include

March 20 | BiosanaPharma released the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®.

06 April 20 | The International Generic and Biosimilar Medicines Association (IGBA) called for urgent priority designation for medicines at custom controls for cargo and freight during the CoVid-19 pandemic. In particular, IGBA highlighted the need for ICU medicines and the goods needed to manufacture them to be moved at greater speeds through ‘green lanes’ .

08 April 20 | NeuClone Pharma announced it had completed monitoring visits and blood sampling for Ph I trials of NeuLara (ustekinumab).

08 April 20 | Pfizer announced FDA had approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News